InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,845.40
(
-0.25%
)
US TECH 100
19,636.20
(
-1.33%
)
Dow Jones
42,938.01
(
-0.30%
)
Brent Oil
73.69
(
-1.64%
)
Bitcoin
65,693.46
(
-0.56%
)
Post# of 253368
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120566
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: poorgradstudent post# 206558

Monday, 02/26/2018 10:14:12 AM

Monday, February 26, 2018 10:14:12 AM

Post# of 253368
ABIO -62% on failed phase-2b for Gencaro in AF:

https://finance.yahoo.com/news/arca-biopharma-reports-topline-phase-130000918.html

ARCA biopharma…today announced clinical results from GENETIC-AF, a Phase 2B, double-blind, superiority clinical trial evaluating Gencaro (bucindolol hydrochloride) as a genetically-targeted treatment for atrial fibrillation (AF) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).

… In all patients, Gencaro demonstrated a similar treatment benefit compared to the active control, TOPROL-XL (143 total events, hazard ratio of 1.01 (95% confidence interval: 0.71, 1.42)…

The primary endpoint was time to recurrence of AF.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up